Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M A Pfaller

Showing results (321-330 of 542) with videos related to

Pageof 55
Sort By:
Journal of Clinical Microbiology|May 8, 2003
Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic locationM A Pfaller, S A Messer, L Boyken, et al.
Antimicrobial Agents and Chemotherapy|October 18, 2002
In vitro activities of 5-fluorocytosine against 8,803 clinical isolates of Candida spp.: global assessment of primary resistance using National Committee for Clinical Laboratory Standards susceptibility testing methodsM A Pfaller, S A Messer, L Boyken, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 6, 2000
Nosocomial bloodstream infections caused by Acinetobacter species in United States hospitals: clinical features, molecular epidemiology, and antimicrobial susceptibilityH Wisplinghoff, M B Edmond, M A Pfaller, et al.
Journal of Clinical Microbiology|November 6, 2004
Evaluation of the etest method using Mueller-Hinton agar with glucose and methylene blue for determining amphotericin B MICs for 4,936 clinical isolates of Candida speciesM A Pfaller, L Boyken, S A Messer, et al.
Journal of Clinical Microbiology|October 6, 2006
Global surveillance of in vitro activity of micafungin against Candida: a comparison with caspofungin by CLSI-recommended methodsM A Pfaller, L Boyken, R J Hollis, et al.
Journal of Clinical Microbiology|November 8, 2005
In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazoleM A Pfaller, L Boyken, R J Hollis, et al.
Journal of Clinical Microbiology|March 7, 2006
In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillanceM A Pfaller, L Boyken, R J Hollis, et al.
Journal of Clinical Microbiology|February 4, 2006
Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida sppS A Messer, D J Diekema, L Boyken, et al.
Journal of Clinical Microbiology|May 1, 2002
Clinical evaluation of a frozen commercially prepared microdilution panel for antifungal susceptibility testing of seven antifungal agents, including the new triazoles posaconazole, ravuconazole, and voriconazoleM A Pfaller, D J Diekema, S A Messer, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 1, 1995
DNA subtypes and fluconazole susceptibilities of Candida albicans isolates from the oral cavities of patients with AIDSF Barchiesi, R J Hollis, D A McGough, et al.
Pageof 55

Showing results (321-330 of 542) with videos related to

Sort By:
Pageof 55
Journal of Clinical Microbiology|May 8, 2003
Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic locationM A Pfaller, S A Messer, L Boyken, et al.
Antimicrobial Agents and Chemotherapy|October 18, 2002
In vitro activities of 5-fluorocytosine against 8,803 clinical isolates of Candida spp.: global assessment of primary resistance using National Committee for Clinical Laboratory Standards susceptibility testing methodsM A Pfaller, S A Messer, L Boyken, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 6, 2000
Nosocomial bloodstream infections caused by Acinetobacter species in United States hospitals: clinical features, molecular epidemiology, and antimicrobial susceptibilityH Wisplinghoff, M B Edmond, M A Pfaller, et al.
Journal of Clinical Microbiology|November 6, 2004
Evaluation of the etest method using Mueller-Hinton agar with glucose and methylene blue for determining amphotericin B MICs for 4,936 clinical isolates of Candida speciesM A Pfaller, L Boyken, S A Messer, et al.
Journal of Clinical Microbiology|October 6, 2006
Global surveillance of in vitro activity of micafungin against Candida: a comparison with caspofungin by CLSI-recommended methodsM A Pfaller, L Boyken, R J Hollis, et al.
Journal of Clinical Microbiology|November 8, 2005
In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazoleM A Pfaller, L Boyken, R J Hollis, et al.
Journal of Clinical Microbiology|March 7, 2006
In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillanceM A Pfaller, L Boyken, R J Hollis, et al.
Journal of Clinical Microbiology|February 4, 2006
Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida sppS A Messer, D J Diekema, L Boyken, et al.
Journal of Clinical Microbiology|May 1, 2002
Clinical evaluation of a frozen commercially prepared microdilution panel for antifungal susceptibility testing of seven antifungal agents, including the new triazoles posaconazole, ravuconazole, and voriconazoleM A Pfaller, D J Diekema, S A Messer, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 1, 1995
DNA subtypes and fluconazole susceptibilities of Candida albicans isolates from the oral cavities of patients with AIDSF Barchiesi, R J Hollis, D A McGough, et al.
Pageof 55